ArticleJournal of human hypertension2026
Blood pressure patterns and cardio-renal complications in primary aldosteronism compared with essential hypertension in a tunisian population.
Article in Journal of human hypertension, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Primary aldosteronism (PA) is a major cause of secondary hypertension associated with increased target organ damage beyond the effects of blood pressure (BP). This study aimed to compare BP characteristics and cardio-renal complications between patients with PA and essential hypertension (EH) in a Tunisian population. We conducted a retrospective study of 227 hospitalized patients (112 with PA and 115 with EH) at a tertiary care center between 2003 and 2023. Clinical, biological, and cardiovascular data were analyzed. Multivariate regression analysis was used to identify independent factors associated with target organ damage, which were more prevalent in PA. Patients with PA had longer hypertension duration, higher systolic and diastolic BP levels, and a higher prevalence of resistant hypertension. Chronic kidney disease (CKD) and left ventricular hypertrophy (LVH) were significantly more frequent in patients with PA (28.7 vs 14.4%; p = 0.01 and 47.4 vs 16.7%; p < 0.001, respectively). After multivariable adjustment, PA remained independently associated with LVH (aOR= 3.1; 95% CI [1.2-7.9]; p = 0.02), whereas its association with CKD was attenuated (p = 0.06; aOR: 2.0 [1.0-4.2]). Baseline aldosterone showed good discriminative ability for LVH (AUC = 0.715; 95% CI: [0.627-0.803]; p < 0.001), with an optimal cut-off value of 135.7 pg/mL. In conclusion, PA was associated with more severe hypertension and a markedly increased risk of LVH compared with EH, supporting a direct deleterious cardiac effect of aldosterone excess and underscoring the importance of early diagnosis and targeted treatment.
Indexed as
Identifiers
42162401What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.